Clinical Trial Update: PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers [Phase 1, Phase 2]

View source ↗

Summary

NCI-sponsored Phase 1/2 trial evaluating PLX038 (PEGylated SN38) in combination with Rucaparib in solid tumors and small cell cancers, with results posted in Ja…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extra-pulmonary Small Cell Carcinomas
• Small Cell Lung Cancer

Drugs mentioned

• PLX038 (PEGylated SN38) (PEGylated SN-38)
• Rucaparib (rucaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-01-03